Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Catechol estrogen metabolites and conjugates in different regions of the prostate of Noble rats treated with 4-hydroxyestradiol: implications for estrogen-induced initiation of prostate cancer.

Authors: Cavalieri, Ercole L; Devanesan, Prabu; Bosland, Maarten C; Badawi, Alaa F; Rogan, Eleanor G

Published In Carcinogenesis, (2002 Feb)

Abstract: Prostate carcinomas arise in 100% of Noble rats treated with estradiol and testosterone. We hypothesize that estrogens initiate prostate cancer mainly by formation of 4-catechol estrogens (CE), followed by their oxidation to catechol estrogen-3,4-quinones (CE-3,4-Q), which can react with DNA. To avoid cancer initiation, CE can be detoxified by catechol-O-methyltransferase (COMT), and CE-3,4-Q by conjugation with glutathione (GSH) or by reduction to CE, catalyzed by quinone reductase and/or cytochrome P450 reductase. To investigate the prostatic metabolism of estrogens, Noble rats were treated with the CE 4-hydroxyestradiol (4-OHE2) or estradiol-3,4-quinone (E2-3,4-Q), and CE metabolites and conjugates were analyzed in the four regions of the prostate, which differ in susceptibility to carcinoma formation. Following treatment of rats with 4-OHE2 (6 micromol/100 g body weight in 200 microl of trioctanoin/dimethylsulfoxide (4:1) by intraperitoneal injection) for 90 min, the non-susceptible ventral (VP) and anterior (AP) prostate had higher levels of 4-methoxyCE and GSH conjugates than the susceptible dorsolateral prostate (DLP) and periurethral prostate (PUP). After treatment with the same molar amount of E2-3,4-Q, the VP and AP contained more GSH conjugates, 4-CE and 4-methoxyCE than the susceptible DLP and PUP. These results suggest that prostate areas susceptible to carcinoma induction have less protection by COMT, GSH, and quinone reductase and/or cytochrome P450 reductase, favoring reaction of CE-3,4-Q with DNA, presumably to initiate cancer.

PubMed ID: 11872641 Exiting the NIEHS site

MeSH Terms: Animals; Caprylates/pharmacology; Catechol O-Methyltransferase/pharmacology; Chromatography, High Pressure Liquid; Dimethyl Sulfoxide/pharmacology; Estradiol/analogs & derivatives*; Estradiol/pharmacology*; Estrogens, Catechol/metabolism*; Estrogens, Catechol/pharmacology; Estrogens/metabolism; Estrogens/pharmacology; Excipients/pharmacology; Glutathione/metabolism; Male; Models, Chemical; NAD(P)H Dehydrogenase (Quinone)/metabolism; NADPH-Ferrihemoprotein Reductase/metabolism; Prostate/drug effects*; Prostatic Neoplasms/chemically induced*; Prostatic Neoplasms/etiology; Prostatic Neoplasms/metabolism*; Protein Binding; Rats; Testosterone/pharmacology; Time Factors; Triglycerides/pharmacology; Urethra/metabolism

Back
to Top